ClinicalTrials.gg
CompletedNCT03241342ASTRIDUpdated Mar 24, 2021Results posted

Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence

A Phase 2 interventional study of GTx 024 and Placebo in Stress Urinary Incontinence, sponsored by GTx. Completed at 62 sites in United States. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-03-24.

Sponsored by GTx · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
491
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 189 studies in Urinary Incontinence, Stress with a site in United States — 27 open to participants now, 40 under way, 3 of them phase 3. Urinary Incontinence, Stress · United States.

Enrollment
11th of 163
491 · median 98
Started
2017
with 14 others
Phase 2
12 of 189
1 open now
Registered
95th of 189
by date
Lead sponsor
4 of 189
GTx

Among the 189 studies in Urinary Incontinence, Stress with a site in United States, this one is the 11th largest by enrollment of the 163 interventional ones that give a count, is one of 15 that started in 2017, is one of 12 in phase 2, and was the 95th registered.

Urinary Incontinence, Stress

653 studies on the registry are indexed under Urinary Incontinence, Stress; 121 are open to participants now.

Browse Urinary Incontinence, Stress studies →

Open to participants now

27 of the 189 studies in Urinary Incontinence, Stress with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 74 Urinary Incontinence, Stress studies recruiting now, 42 (57%) set no upper age limit and 18 (24%) stop at 75 or younger; 2 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Urinary Incontinence, Stress with a site in United States, or all of them as a file.
02

Study summary

GTx-024 is an orally bioavailable and tissue-selective nonsteroidal selective androgen receptor modulator (SARM) that has demonstrated androgenic and anabolic activity and is currently being evaluated as a potential treatment for stress urinary incontinence (SUI) in postmenopausal women. Urinary incontinence and pelvic floor disorders are major health problems for women, especially as they age. Pelvic floor muscle relaxation has been found to correlate with lower urinary tract symptoms including SUI. Muscles of the pelvic floor and lower urinary tract are crucial for supporting the pelvic organs and micturition; however, damage to the muscles or lack of hormonal stimulation are thought to contribute to pelvic organ prolapse and urinary incontinence. Although anabolic steroids may increase muscle mass and strength, lack of oral bioavailability and known potential risks have limited their use. Nonsteroidal SARMs have potential to achieve benefits of anabolic steroid therapy (improved muscle mass, cholesterol/triglyceride levels, glucose metabolism, and bone density) with fewer adverse effects, such as hirsutism and acne, in women. Both nonclinical and clinical data suggest that SARMs may provide a new therapeutic option for pelvic floor and lower urinary tract disorders, as both testosterone and its more potent metabolite, dihydrotestosterone, have anabolic effects on muscle.

03

Conditions studied

  • Stress Urinary Incontinence
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • SUI symptoms of at least 6 months duration
  • Predominant SUI as determined at the Screening Visit using the Medical, Epidemiological, and Social Aspects of Aging (MESA) urinary questionnaire.
  • 24-Hour pad weight > 3 g during the screening period
  • A minimum of 1 and no more than 15 SUI episodes on any single day AND no fewer than 9 total SUI episodes over 3 days during the screening period
  • Positive bladder stress test conducted during the Screening Visit

Key Exclusion Criteria:

  • History of pelvic radiation treatment
  • History of urethral diverticula
  • History of urethral sling or anterior prolapse repair
  • Treatment with urethral bulking agents and/or other SUI procedure or surgery within the 6 months prior to the Screening Visit
  • Known vesicoureteral reflux, vaginal prolapse beyond the introitus, or other significant pelvic floor abnormalities
  • Urinary incontinence of neurogenic etiology
  • Morbidly obese (defined as 100 pounds over ideal body weight, or 40 or greater)
  • Chronic hepatitis
  • Hepatic cirrhosis
  • Evidence of active infection with or
  • History of (HIV) infection
  • Subjects with a history of breast or endometrial cancer
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
491 participants (actual)

Study arms

  • Active comparator
    1 mg GTx-024

    Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.

    Drug: GTx 024

  • Active comparator
    3 mg GTx-024

    Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.

    Drug: GTx 024

  • Placebo comparator
    matching placebo

    Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.

    Drug: Placebo

Interventions

  • Study drug is an opaque, white to off-white, size 5, oval Softgel capsule containing the active ingredient GTx-024.

    Also known as: Enobosarm

  • DrugPlacebo

    Placebo study drug is identical in appearance to the GTx-024 study drug and contains polyethylene glycol 400 but not GTx-024.

06

What researchers measure

Primary outcomes

  1. Number of Participants With a ≥ 50% Reduction From Baseline in the Mean Number of Stress Incontinence Episodes Per Day at Week 12

    Mean number of subject-reported stress incontinence episodes per day through a responder analysis, where a responder is defined as having a ≥ 50% reduction at the end of treatment (Week 12) compared to baseline in the number of stress incontinence episodes

    Time frame: 12 Weeks

07

Results

Posted Nov 12, 2020

Participant flow

Participant flow — Overall Study
Milestone1 mg GTx-0243 mg GTx-024Matching Placebo
Started163163165
Completed141132138
Not completed223127
Withdrew: Adverse event584
Withdrew: Lack of efficacy001
Withdrew: Noncompliance with study drug211
Withdrew: Sponsor decision012
Withdrew: Not reported152119

Outcome measures

PrimaryNumber of Participants With a ≥ 50% Reduction From Baseline in the Mean Number of Stress Incontinence Episodes Per Day at Week 12

Mean number of subject-reported stress incontinence episodes per day through a responder analysis, where a responder is defined as having a ≥ 50% reduction at the end of treatment (Week 12) compared to baseline in the number of stress incontinence episodes

Time frame:
12 Weeks
Reported as:
Count of participants · Participants
Number of Participants With a ≥ 50% Reduction From Baseline in the Mean Number of Stress Incontinence Episodes Per Day at Week 12
Participants1 mg GTx-0243 mg GTx-024Matching Placebo
Number of Participants With a ≥ 50% Reduction From Baseline in the Mean Number of Stress Incontinence Episodes Per Day at Week 12949687

Adverse events

Collected over 7 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1 mg GTx-0240/163 (0%)3/163 (1.8%)105/163 (64.4%)
3 mg GTx-0240/163 (0%)2/163 (1.2%)104/163 (63.8%)
Matching Placebo0/165 (0%)4/165 (2.4%)96/165 (58.2%)
Most frequent serious events
Most frequent serious events
Event1 mg GTx-0243 mg GTx-024Matching Placebo
acute myocardial infarctionCardiac disorders1/1630/1630/165
goiterEndocrine disorders0/1631/1630/165
hip fractureInjury, poisoning and procedural complications1/1630/1630/165
cerebral vascular accidentNervous system disorders0/1631/1630/165
dysaesthesiaNervous system disorders1/1630/1630/165
abscessed limbInfections and infestations0/1630/1631/165
osteomyelitisInfections and infestations0/1630/1631/165
spinal disorderMusculoskeletal and connective tissue disorders0/1630/1631/165
pulmonary congestionRespiratory, thoracic and mediastinal disorders0/1630/1631/165
respiratory failureRespiratory, thoracic and mediastinal disorders0/1630/1631/165
Most frequent other events
Showing 10 of 242
Most frequent other events
Event1 mg GTx-0243 mg GTx-024Matching Placebo
urinary tract infectionInfections and infestations17/16329/16318/165
headacheNervous system disorders3/16312/1637/165
upper respiratory tract infectionInfections and infestations7/1637/16310/165
oedema peripheralGeneral disorders7/1633/1631/165
nasopharyngitisInfections and infestations4/1637/1636/165
blood creatinine increaseInvestigations7/1630/1631/165
nauseaGastrointestinal disorders4/1634/1637/165
hypertensionVascular disorders3/1636/1632/165
dry mouthGastrointestinal disorders1/1635/1634/165
insomniaPsychiatric disorders0/1635/1631/165

Baseline characteristics

Age, Continuous
Age, Continuous(years)1 mg GTx-0243 mg GTx-024Matching PlaceboTotal
Median60 (42 to 80)59 (40 to 79)58 (44 to 80)59 (40 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)1 mg GTx-0243 mg GTx-024Matching PlaceboTotal
Female163163165491
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)1 mg GTx-0243 mg GTx-024Matching PlaceboTotal
Hispanic or Latino13101538
Not Hispanic or Latino149152150451
Unknown or Not Reported1102
Race (NIH/OMB)
Race (NIH/OMB)(Participants)1 mg GTx-0243 mg GTx-024Matching PlaceboTotal
American Indian or Alaska Native3216
Asian1113
Native Hawaiian or Other Pacific Islander0011
Black or African American25201257
White131139150420
More than one race0000
Unknown or Not Reported3104
Baseline number of stress incontinence episodes per day
Baseline number of stress incontinence episodes per day(episodes per day)1 mg GTx-0243 mg GTx-024Matching PlaceboTotal
Mean4.588 (3 to 11.67)4.329 (3 to 12.67)4.459 (3 to 12)4.4 (3 to 12.67)
08

Study locations

62 sites
  • Urology Center of Alabama
    Homewood, Alabama 35209, United States
  • Coastal Clinical Research Inc
    Mobile, Alabama 36608, United States
  • Alaska Clinical Research Center
    Anchorage, Alaska 99503, United States
  • Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
  • Urological Associates of Southern Arizona
    Tucson, Arizona 85741, United States
  • Women's Healthcare Research Corporation
    San Diego, California 92111, United States
  • American Institute of Research
    Whittier, California 90603, United States
  • Genitourinary Surgical Consultants
    Denver, Colorado 80220, United States
  • Urology Associates Research
    Englewood, Colorado 80113, United States
  • Women's Health Specialty Care
    Farmington, Connecticut 06032, United States
  • Coastal Connecticut Research, LLC
    New London, Connecticut 06320, United States
  • Bladder Control Center of Connecticut
    Norwalk, Connecticut 06859, United States
  • James A Simon MD PC
    Washington, District of Columbia 20036, United States
  • South Florida Medical Research
    Aventura, Florida 33180, United States
  • Tampa Bay Medical Research Inc
    Clearwater, Florida 33761, United States
  • Midland Florida Clinical Research Center LLC
    DeLand, Florida 32720, United States
  • Precision Clinical Research
    Lauderdale Lakes, Florida 33319, United States
  • Lone Star Research Center
    Miami, Florida 33145, United States
  • Medical Research of Florida
    Miami, Florida 33186, United States
  • Clinical Research Center of Florida
    Pompano Beach, Florida 33060, United States
  • Mount Vernon Clinical Research LLC
    Sandy Springs, Georgia 30328, United States
  • Clinical Research Prime
    Idaho Falls, Idaho 83221, United States
  • Idaho Urologic Institue
    Meridian, Idaho 83642, United States
  • Women's Health Institution of Illinois
    Oak Lawn, Illinois 60453, United States
  • First Urology PSC
    Jeffersonville, Indiana 47130, United States
  • Iowa Clinic
    West Des Moines, Iowa 50266, United States
  • DelRicht Clinical Research, LLC
    New Orleans, Louisiana 70115, United States
  • Regional Urology
    Shreveport, Louisiana 71106, United States
  • Chesapeake Urology Associates PA
    Hanover, Maryland 21076, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • Bay State clinical Trials
    Watertown, Massachusetts 02472, United States
  • Beyer Research
    Kalamazoo, Michigan 49009, United States
  • William Beaumont Hospital Urology Research
    Royal Oak, Michigan 48073, United States
  • Women's Clinic of Lincoln
    Lincoln, Nebraska 68510, United States
  • Sheldon J Freedman MD Ltd
    Las Vegas, Nevada 89144, United States
  • Premier Urology Group, LL
    Edison, New Jersey 08837, United States
  • Lawrence Obs Gyn clinical Research
    Lawrenceville, New Jersey 08648, United States
  • Delaware Valley Urology
    Mount Laurel, New Jersey 08054, United States
  • Accumed Research Associates
    Garden City, New York 11530, United States
  • Manhattan Medical Research Practice PLLC
    New York, New York 10016, United States
  • Premier Medical Group
    Poughkeepsie, New York 12601, United States
  • Circuit Clinical
    West Seneca, New York 14224, United States
  • American Health Research Inc
    Charlotte, North Carolina 28207, United States
  • Alliance Urology Specialist PA
    Greensboro, North Carolina 27403, United States
  • Eastern Carolina Women's
    New Bern, North Carolina 28562, United States
  • The Urology Group
    Cincinnati, Ohio 45212, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Aventiv Research
    Columbus, Ohio 43213, United States
  • Institute for Female Pelvic Medicine
    Allentown, Pennsylvania 18103, United States
  • Urologic Consultants of Southeastern PA LLP
    Bala-Cynwyd, Pennsylvania 19004, United States
  • University of Pennsylvania Health System
    Philadelphia, Pennsylvania 19104, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • Carolina Urologic Research
    Myrtle Beach, South Carolina 29572, United States
  • The Jackson Clinic
    Jackson, Tennessee 38305, United States
  • Elligo - Austin Area OBGYN
    Austin, Texas 78758, United States
  • Urology Clinics of North Texas
    Dallas, Texas 75231, United States
  • Clinical Trials of Texas Incorporated
    San Antonio, Texas 78229, United States
  • Urology San Antonio Research PA
    San Antonio, Texas 78229, United States
  • Synexus Clinical Research Advantage, Inc. - Wasatch Peak Family Practice
    Layton, Utah 84041, United States
  • Urology of Virginia
    Virginia Beach, Virginia 23462, United States
  • Urology Northwest PS
    Mountlake Terrace, Washington 98043, United States
  • Seattle Womens: Health, Research, Gynocology
    Seattle, Washington 98105, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Sep 2018, 13 months.

Results were first posted in Nov 2020, 2 years 1 month after primary completion.

Of 15 phase 2 interventional studies under Urinary Incontinence, Stress, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2017
First posted
Aug 7, 2017
StartActual
Aug 21, 2017
Primary completionActual
Sep 21, 2018
CompletionActual
Sep 21, 2018
Results first posted
Nov 12, 2020
Last update
Mar 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03241342
Lead sponsor
GTx
Responsible party
Sponsor
First posted
Aug 7, 2017
Start date
Aug 21, 2017
Primary completion
Sep 21, 2018
Completion
Sep 21, 2018
Results posted
Nov 12, 2020
Last update
Mar 24, 2021

Study contacts

Kenneth M Peters, MD
principal investigator · Oakland University, William Beaumont School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ostarine

Start the discussion